HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $41 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.3%

Neg 0% Neu 90.3% Pos 0%

HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $41 price target.